A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
Status:
Recruiting
Trial end date:
2022-10-17
Target enrollment:
Participant gender:
Summary
This is an open-label, fixed-sequence study to evaluate the effect of capivasertib on the
pharmacokinetics (PK) of midazolam, a sensitive CYP3A substrate. The PK of midazolam will be
assessed when administered alone and in combination with repeated doses of capivasertib.